Key facts
- MayBio Biomedical’s last known valuation is $11.4M (Aug 2020).
- It has raised $2.9M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Hunan Chasing Fund, Alwin Capital, Century Golden Resources Group, Beijing New Aerotropolis Fund Management, Kefu Medical — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for MayBio Biomedical
- ·The full record, as it builds
Funding rounds
No funding rounds for MayBio Biomedical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MayBio Biomedical
Developer of surgical implant products containing human extracellular matrix and collagen designed for medical beauty. The company is committed to providing a series of overall medical solutions including cells, biomaterials, human growth factors and human collagen, enabling medical professionals to have better medical products to use.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2019
- Website
- maybio.cn/
- Ownership
- Privately Held (backing)
MayBio Biomedical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MayBio Biomedical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MayBio Biomedical in its N-PORT filings yet. We sweep new filings monthly.